Skip to content
Fast Facts
Fast Facts
Supporting Access to Our Innovators  Fast Fact
Our Rebates, Discounts and Fees in 2020
$29.4 billion – Rebates, discounts and fees provided in 2020 to payers and others in the health system – more than half the list price (53%) of our medicines.
Fast Fact: Increases in Cost-Sharing Impact Adherence
Cost-Sharing Increases Affect Adherence
Doubling co-pays has been found to reduce patients’ adherence to prescribed medicines by 25%–45%.
Reducing Patient Out-of-Pocket Costs in Part D
Reducing Patient Out-of-Pocket Costs in Part D
Tying cost-sharing to net price would result in 47% of Medicare beneficiaries would see reduction in out-of-pocket spending
Growth Rate of 340B Program
Growth Rate of the 340B Program
The 340B Drug Discount Program tripled in size between 2014 and 2019 to nearly $30 billion
Fast Facts: Growth Rate of 340B Program (stats)
Growth Rate of the 340B Program
In recent years the 340B program has expanded at double-digit rates
This year, we offer a more detailed look at the price reductions we offer payers and others in the healthcare system to support access to our medicines.

We launched our first annual Janssen U.S. Transparency Report four years ago because we wanted to provide policymakers and patients with useful information about what drives the cost of healthcare, including the cost of prescription medicines. We wanted to shed light on the aspects of our health system that stood in the way of patients getting needed care and ultimately, advance the dialogue about how to deliver greater access to medicines at a more manageable cost.

Internet Explorer is not supported by this website.

For optimal browsing we recommend using Chrome, Safari, or Firefox.